Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium


This study is intended to determine whether the addition of trospium chloride to xanomeline tartrate will ameliorate the peripheral cholinergic side effects that have been previously experienced with xanomeline tartrate when administered alone.

Full Title of Study: “A Phase I, Double-Blind, Randomized, Multiple-Dose, Pilot Study Comparing Xanomeline Administered Alone to Xanomeline Administered in Combination With Trospium Chloride in Normal Healthy Volunteers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: October 28, 2016

Detailed Description

In this inpatient study, volunteers will received either xanomeline alone, or xanomeline plus trospium for 7 days. Subjects will report cholinergic side effects daily via visual analog scales, for each of nausea, vomiting, diarrhea, sweating and excessive salivation. Clinician administered scales will also be administered daily for assessment of the same cholinergic side effects.


  • Drug: xanomeline tartrate
    • xanomeline tartrate, 75 mg capsule, TID
  • Drug: Trospium chloride
    • trospium chloride, over encapsulated 20 mg tablet, BID

Arms, Groups and Cohorts

  • Active Comparator: Xanomeline plus placebo
    • Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Placebo, TID
  • Experimental: Xanomeline plus trospium
    • Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Drug: Trospium chloride 20 mg BID, for a 40 mg total daily dose

Clinical Trial Outcome Measures

Primary Measures

  • Mean weekly maximum composite Visual Analogue Scale (VAS) score (nausea, diarrhea, sweating, salivation and vomiting combined) comparing xanomeline + placebo to xanomeline + trospium
    • Time Frame: 7 days

Participating in This Clinical Trial

Inclusion Criteria

  • Female subjects must be postmenopausal (at least 2 years prior to dosing) or agree to use an acceptable form of birth control from screening until 14 days after completion of the study. If on birth control pills, have been on a stable dose for≥12 months. – Good general health – Ability to give informed consent and understand verbal instructions – Willingness to spend 10 days in an in-patient facility Exclusion Criteria:

  • History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results. (Subjects with any history of resolved cancer that is >5 years passed can be included.) – Body Mass Index <18 or > 40 kg/m2 – History of or high risk of urinary retention, gastric retention, or narrow-angle glaucoma – History of alcohol or drug abuse within the last 24 months, or current abuse as determined by urine toxicology screen – Clinically significant abnormal finding on the physical exam, medical history, ECG, or clinical laboratory results at screening – Has participated in another clinical trial within 90 days prior to the first dose of study medication – Needs to take any prescription medication besides the investigational product or those specifically noted above. Use of any vitamins, herbs, supplements, or over the counter medications are excluded within one week of enrollment, and during the course of the trial. Specifically, subjects may not take Benadryl® for one week prior and during the course of the study. – Use of any tobacco products within the past 30 days – Previous positive test for HIV 1 and/or 2, or Hepatitis A, B, or C, or a positive test obtained at screening.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Karuna Therapeutics
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Lukasz Biernat, PhD, Principal Investigator, Medpace, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.